Literature DB >> 19240110

Patients with non-ischaemic dilated cardiomyopathy and hyper-responders to cardiac resynchronization therapy: characteristics and long-term evolution.

Philippe Castellant1, Marjaneh Fatemi, Erwann Orhan, Yves Etienne, Jean Jacques Blanc.   

Abstract

AIMS: In some patients with non-ischaemic dilated cardiomyopathy (NIDCM), left bundle branch block (LBBB), and severe cardiac failure, cardiac resynchronization therapy (CRT) has been shown to reverse almost completely left ventricular (LV) function. These patients thus eligible to be qualified 'hyper-responders' are exclusively recruited in patients with NIDCM. Evaluate proportion of 'hyper-responders' among patients with NIDCM and try to determine their profile before implantation of CRT. METHODS AND
RESULTS: Consecutive patients with DCM [LV ejection fraction (LVEF) <35%, LV end-diastolic diameter >60 mm], sinus rhythm, LBBB, and New York Heart Association (NYHA) class III and IV implanted with a CRT were prospectively followed. Patients were considered 'hyper-responders' if they fulfilled after a minimum period of 6 months the following criteria: functional recovery (NYHA class I or II) and LVEF >or=50%. Among the 51 NIDCM patients, 11 (21.5%) were 'hyper-responders' following CRT (LVEF increased from 26 +/- 9 to 59 +/- 6%, P < 0.01). In the 40 (78.5%) remaining patients, there was no or minimal functional improvement and only a modest increase in LVEF from 21 +/- 9 to 26 +/- 12% (P = 0.03). Comparison between 'hyper-responders' and remaining patients showed that baseline parameters of 'hyper-responders' were less severely deteriorated.
CONCLUSION: In a significant subset of patients with CRT for NIDCM, a 'complete' functional recovery associated with normalization of LV function was observed. This observation suggests that LBBB could be the causative factor of DCM in this subgroup of patients. There was not a unique discriminating factor at baseline between 'hyper-responders' and remaining patients.

Entities:  

Mesh:

Year:  2009        PMID: 19240110     DOI: 10.1093/europace/eup035

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  13 in total

Review 1.  Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure.

Authors:  Yitschak Biton; Jayson R Baman; Bronislava Polonsky
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

2.  Native QRS narrowing reflects electrical reversal and associates with anatomical reversal in cardiac resynchronization therapy.

Authors:  Xin-wei Yang; Wei Hua; Jing Wang; Zhi-min Liu; Li-gang Ding; Ke-ping Chen; Shu Zhang
Journal:  J Interv Card Electrophysiol       Date:  2014-09-17       Impact factor: 1.900

3.  Prophylactic implantable defibrillators in dilated cardiomyopathy.

Authors:  W Grimm
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

4.  Regression of fragmented QRS complex: a marker of electrical reverse remodeling in cardiac resynchronization therapy.

Authors:  Xin-wei Yang; Wei Hua; Jing Wang; Zhi-min Liu; Li-gang Ding; Ke-ping Chen; Shu Zhang
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-07-07       Impact factor: 1.468

5.  Is "hyper response" to cardiac resynchronization therapy in patients with nonischemic cardiomyopathy a recovery, a remission, or a control?

Authors:  Philippe Castellant; Erwann Orhan; Valerie Bertault-Valls; Marjaneh Fatemi; Yves Etienne; Jean-Jacques Blanc
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-10       Impact factor: 1.468

6.  Evaluation of super-responders to cardiac resynchronization therapy in the presence of left bundle branch block and absence of scar in the posterolateral wall of the left ventricle.

Authors:  Izaias Marques de Sá Junior; José Carlos Pachón Mateos; Juan Carlos Pachón Mateos; Remy Nelson Albornoz Vargas
Journal:  Am J Cardiovasc Dis       Date:  2020-04-15

7.  Hyper-response to cardiac resynchronization with permanent His bundle pacing: Is parahisian pacing sufficient?

Authors:  Olujimi A Ajijola; Jorge Romero; Gabriel Vorobiof; William M Suh; Kalyanam Shivkumar; Roderick Tung
Journal:  HeartRhythm Case Rep       Date:  2015-09-03

8.  Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation.

Authors:  Zhinian Guo; Xiaoyan Liu; Chuan Liu; Jie Yang; Xiaofeng Cheng; Yunlong Chen; Ping Li; Yongming He; Jiang Wang
Journal:  Biomed Res Int       Date:  2019-06-24       Impact factor: 3.411

9.  Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study.

Authors:  Eloi Marijon; Christophe Leclercq; Kumar Narayanan; Serge Boveda; Didier Klug; Jonathan Lacaze-Gadonneix; Pascal Defaye; Sophie Jacob; Olivier Piot; Jean-Claude Deharo; Marie-Cecile Perier; Genevieve Mulak; Jean-Sylvain Hermida; Paul Milliez; Daniel Gras; Olivier Cesari; Françoise Hidden-Lucet; Frederic Anselme; Philippe Chevalier; Philippe Maury; Nicolas Sadoul; Pierre Bordachar; Serge Cazeau; Michel Chauvin; Jean-Philippe Empana; Xavier Jouven; Jean-Claude Daubert; Jean-Yves Le Heuzey
Journal:  Eur Heart J       Date:  2015-09-01       Impact factor: 29.983

10.  Measures of endothelial dysfunction predict response to cardiac resynchronisation therapy.

Authors:  David R Warriner; Patricia Lawford; Paul J Sheridan
Journal:  Open Heart       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.